<DOC>
	<DOCNO>NCT02943993</DOCNO>
	<brief_summary>According current guideline , duration anticoagulant treatment venous thromboembolic event varies 3 month indefinite treatment depend estimate risk venous thromboembolism ( VTE ) recurrence bleeding . Current data edoxaban limit maximum treatment duration 12 month ( Hokusai-VTE ; N Engl J Med . 2013 ; 369:1406-15 ) . Therefore , study aim gather insight efficacy ( i.e . symptomatic recurrent VTE ) safety ( i.e . bleed event , liver adverse event , all-cause mortality drug relate adverse event ) extend treatment edoxaban 18 month unselected patient population routine clinical practice .</brief_summary>
	<brief_title>Edoxaban Treatment Routine Clinical Practice Patients With Venous Thromboembolism Europe</brief_title>
	<detailed_description>Real-world evidence data routine clinical practice use edoxaban 18 month collect 2,700 patient , treat specialized well non-specialized physician hospital office base centre 11 European country . Patients different country care setting ( primary care secondary care , different specialty ) ensure representativeness extend assessment plan collection VTE recurrences 18 month last data collection point patient enter study early . The enrollment period patient 2 year per country . Documentation baseline follow information 1 , 3 , 6 , 12 , 18 month ( available ) collect . In addition , recurrence symptomatic VTE death capture retrospectively time point Last Patient Out per country . Patients discontinue permanently edoxaban observational period follow accord scheme . The result gain ETNA-VTE-Europe compare data PREFER VTE disease registry . The PREFER registry , select similar bleeding definition , comparable data collection point schedule , robust number patient ( ~3,500 patient ) enrol .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Established acute initial recurrent VTE Patients prescribe treatment edoxaban accord Summary Product Characteristics ( SmPC ) participation trial Written inform consent participation study ( ICF ) Not simultaneously participate interventional study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Post-Authorisation Safety Study</keyword>
	<keyword>Real World Evidence</keyword>
	<keyword>Edoxaban</keyword>
	<keyword>Efficacy/Safety</keyword>
</DOC>